First Trust Nasdaq Pharmaceuticals ETF
FTXH
NASDAQ Global Market- -
USD
- -
- -
- -
- -
(- -)
Recent
price
- -
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that provides exposure to U.S. companies within the pharmaceuticals sector by tracking the Nasdaq US Smart Pharmaceuticals Index. The fund invests at least 90% of its net assets in securities comprising the index, which selects approximately 30 of the most liquid U.S. pharmaceutical companies and weights them using a modified factor-based methodology incorporating value, volatility, and growth metrics; top holdings include Johnson & Johnson, AbbVie Inc., Merck & Co., Inc., Pfizer Inc., and Bristol-Myers Squibb Company, representing pharmaceuticals, biotechnology, and life sciences firms developing and distributing prescription drugs, biologics, vaccines, and related healthcare products and services. FTXH operates exclusively in the U.S. equity markets, targeting institutional and retail investors seeking sector-specific exposure to large- and mid-cap pharmaceutical leaders alongside biotechnology innovators; it was launched on September 20, 2016, and is managed by First Trust Advisors L.P., whose parent entities First Trust Portfolios L.P. and First Trust Advisors L.P. maintain headquarters in Wheaton, Illinois. In recent developments, FTXH achieved a new 52-week high in November 2025 amid a pharma sector rally fueled by regulatory tailwinds, Federal Reserve rate cuts, and AI adoption in healthcare, with assets under management reaching approximately $18.9 million and a one-year NAV return of -1.35% contrasted by strong short-term gains including 37.2% from its 52-week low.